Ország: Malajzia
Nyelv: angol
Forrás: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)
AMOXYCILLIN; CLARITHROMYCIN; PANTOPRAZOLE
ABBOTT LABORATORIES (M) SDN. BHD.
AMOXYCILLIN; CLARITHROMYCIN; PANTOPRAZOLE
28 Tablets; 14 Tablets
ZUELLIG PHARMA SDN BHD
PRODUCT INFORMATION This document refers to the use of pantoprazole, clarithromycin and amoxycillin in combination for the treatment of patients with peptic ulcer disease. The components of this therapy are frequently used to treat other conditions. For information about the treatment of conditions other than peptic ulcer disease, refer to full Product Information for the appropriate component. NAME OF DRUG KLACID ® Hp is a combination pack containing Klacid ® (active ingredient clarithromycin) 500mg tablet, Controloc (active ingredient pantoprazole sodium sesquihydrate 45.1mg which is equivalent to pantoprazole 40mg) 40mg tablet, and Ospamox (active ingredient amoxicillin) 1gm tablet. DESCRIPTION KLACID ® pale yellow ovaloid film-coated tablet. CONTROLOC yellow, oval, biconvex enteric-coated tablets with a white to off-white core printed with brown ink, on one side: P40. OSPAMOX white to cream coloured tablet, oblong, biconvex, with break scores on both sides. PHARMACOLOGY KLACID ® Hp Helicobacter pylori is a spiral, flagellated, Gram-negative rod, primarily colonising the antrum of the stomach, it congregates at, and around intercellular junctions. The natural habitat of H.pylori is the gastric mucosa, where the bacterium attaches itself via adhesion pedestals. H.pylori is associated with duodenal and gastric ulcer disease in about 95% and 70% of patients, respectively. H.pylori is the major factor in the development of gastritis and ulcers in such patients. Eradication of H.pylori is associated with reduced peptic ulcer recurrence. Eradication of H.pylori is therefore appropriate therapy in most patients with duodenal and gastric ulcer where the latter is not caused by non-steriodal anti-inflammatory drug (NSAID) ingestion. Eradication of H.pylori was achieved in approximately 95% of patients following therapy with clarithromycin, pantoprazole and amoxycillin. KLACID ® Clarithromycin is active in vitro and in vivo against H.pylori. Clarithromycin exerts its antibacterial action by binding to the 50s ribos Olvassa el a teljes dokumentumot